
Calliditas Interim Report Q3, 2019
Positive Regulatory Outcome – Enhanced study design
“This…

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
In Phase 2b development for the treatment of life-threatening…

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov.…

IXICO to Present Abstracts at Upcoming Huntington’s Disease and Ataxia Conferences
IXICO plc (AIM: IXI), the AI data analytics company delivering…

Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH
-Neuraxpharm establishes Swiss footprint with acquisition of…

IXICO announces client contracts and appointment of Chief Business Officer
IXICO plc (AIM: IXI), the AI data analytics company delivering…

Kiadis Pharma announces formation of renowned Scientific Advisory Board
Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma…

Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
Results to Inform Development Plan and Dose Selection for Phase…

IXICO Company reports fast tracked achievement of initial year positive EBITDA, 40% revenue growth and strong cash position
IXICO plc (AIM: IXI), the AI data analytics company delivering…

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:…

ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank
The European Investment Bank and ISA Pharmaceuticals have signed…

Castor Announces International Expansion to Meet Growing Demand for an AI-Powered Clinical Data Platform
Castor establishes new US operations, building on leadership…

Owkin publishes breakthrough research in Nature Medicine
Novel deep-learning approach for predicting and explaining the…

Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon
Calliditas Therapeutics AB (publ) (“Calliditas”) today…

Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
Cambridge, UK and New York, US, 24 September 2019. Artios Pharma…

Neuraxpharm provides business update on a transformational year
Neuraxpharm Group (Neuraxpharm), a leading European specialty…

Optimum’s 11th Annual Healthcare Investor Conference
17 OCT 2019 | London

HOX THERAPEUTICS TO PRESENT AT 2019 AACR ANNUAL MEETING
Guildford, UK – 06 February 2019: HOX Therapeutics, the private…

DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy
Turku, Finland – 18 December 2018: DelSiTech Ltd, a Finnish…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York